Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 81

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 81
---
                  
 of 15%. This medication for chronic weight management has a list price of approximately $1,350 for a 28-day supply, totaling over            
 $16,000 annually without insurance or manufacturer discounts.                                                                                |
| ● | Sanofi                                                                                                                                       
 (NASDAQ: SNY) – SNY is developing rimonabant (Acomplia), the first CB1 receptor antagonist approved in Europe in 2006 for obesity.           
 It was withdrawn in 2008 due to depression and suicide risks. Since then, Sanofi has not publicly pursued a new CB1 antagonists,             
 shifting focus to other metabolic therapies like diabetes drugs.                                                                             |
| ● | Pfizer                                                                                                                                       
 Inc. (NYSE: PFE) – PFE is developing otenabant (CP-945,598), a CB1 antagonists and selective inverse agonist for obesity and                 
 metabolic disorders. It reached Phase 3 trials but was discontinued in 2008 due to psychiatric risks similar to those of rimonabant          
 and a strategic shift away from this class after rimonabant’s withdrawal.                                                                    |

Despite the foregoing, SKNY believes that its SKNY-1 presents the unique property of acting as a CB1 blocker, CB2 activator and a selective MAO-B inhibitor without side effects.

Smoking Cessation Market Overview

The smoking cessation market in 2025 is a dynamic and growing sector driven by increasing global awareness of the health risks associated with smoking, government initiatives to reduce tobacco use, and advancements in cessation products and therapies. The global smoking cessation and nicotine de-addiction market is experiencing robust growth. Estimates suggest the market was valued at approximately $25.5 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of around 10-12% from 2025 to the early 2030s. By 2030-2034, the market size could reach between $53.87 billion and $71.5 billion, depending on various forecasts. This growth is fueled by rising demand for nicotine replacement therapies (NRT), e-cigarettes, and innovative cessation aids, alongside increasing quitting attempts worldwide. (Source: http://www.researchandmarketingreview.comand http://www.gminsights.com)

| 42 |

Key Drivers

Growing recognition of smoking-related diseases—such as lung cancer, cardiovascular issues, and respiratory disorders—continues to push individuals toward cessation. Public health campaigns by organizations like the World Health Organization (“WHO”) and local governments amplify this trend (